Kodiak CFO Switches Gears: Buys 28,614 Shares After Daily Sell‑Off, Hinting at Insider Confidence in Biopharma Pivot.
See why Kodiak Sciences’ CFO’s buy‑the‑dip move may signal long‑term confidence in the company’s retinal‑disease pipeline.
3 minutes to read


